Previous Article | Next Article 
Journal of Virology, December 1998, p. 9470-9478, Vol. 72, No. 12
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Replication of ONYX-015, a Potential Anticancer
Adenovirus, Is Independent of p53 Status in Tumor Cells
Thomas
Rothmann,
Arnd
Hengstermann,
Noel J.
Whitaker,
Martin
Scheffner, and
Harald
zur Hausen*
Angewandte Tumorvirologie, Deutsches
Krebsforschungszentrum, 69120 Heidelberg, Germany
Received 1 June 1998/Accepted 20 August 1998
 |
ABSTRACT |
The 55-kDa E1B protein of adenovirus, which binds to and
inactivates the tumor suppressor protein p53, is not expressed in the
adenoviral mutant termed ONYX-015 (i.e., dl1520). It was
reported that the mutant virus due to a deletion in E1B is able to
replicate only in cells deficient for wild-type p53. Accordingly,
dl1520 is currently being evaluated as a potential tool in
the therapy of p53 deficient cancers. In contrast, we report here that
dl1520 replicates independently of the p53 status in
various tumor cell lines (U87, RKO, A549, H1299, and U373). In
addition, the inhibition of p53-mediated transcriptional activation in
wild-type p53 containing U2OS cells, by overexpression of a
transdominant negative p53 mutant, did not render the cells permissive
for dl1520 replication. Finally, we show that, depending on
the multiplicity of infection, the deleted virus is able to replicate
in and to kill primary human cells. Thus, the molecular basis for the
growth differences of dl1520 within different cell types
remains to be determined.
| |
INTRODUCTION |
Replication-defective recombinant
adenoviruses are widely used as gene therapeutic vectors in clinical
protocols, including several for the treatment of cancer
(25). Compared with other vector systems, adenoviruses
efficiently mediate gene transfer into a large number of tissue types.
Yet, the desirable objective of reaching all or most of the tumor cells
within a given cancer, while leaving healthy tissue unaffected, is
still far from a reality (36). Recently, a new concept has
been developed based on an adenovirus mutant (ONYX-015), which
reportedly replicates efficiently only in tumor cells and which appears
to overcome this limitation (7). The apparently
tumor-restricted adenovirus was originally constructed by Barker and
Berk (5) and is called dl1520. The basis for the
described tumor specificity has been postulated to be a genetic
deletion of the viral E1B gene function, resulting in the loss of
the expression of the viral 55-kDa protein (E1B 55K) (5).
E1B 55K is known to bind to the tumor suppressor protein p53 and, as a
consequence, to block p53-mediated transcriptional activation (28,
37, 38). Bischoff et al. (7) surmised that the binding
of E1B 55K to p53 is necessary for efficient wild-type (wt) adenovirus
replication in p53-positive cells. In support of this hypothesis,
Bischoff et al. presented data indicating that replication of
ONYX-015 (i.e., dl1520) was restricted to wt
p53-deficient tumor cells. Since loss of function of the p53 tumor suppressor gene occurs in more than 50% of all types of human
cancers (14, 18), the virus was proposed to be widely applicable in cancer therapy. Accordingly, phase I clinical trials have
been initiated in head and neck cancer patients and are now being
expanded to phase II. In addition, phase I trials have been initiated
in patients with pancreatic cancer, ovarian cancer, and
gastrointestinal cancer with liver metastasization. More recently, the
same investigators reported that dl1520 is also able to
replicate in some p53-positive tumor cells but not in primary cells
of multiple origin (13). We also found replication of
dl1520 in p53-positive tumor cells, including U87 and RKO
cells, described by Bischoff et al. (7) and Heise et al.
(13) to be resistant to dl1520 replication.
Furthermore, we could show that p53-negative U373 cells are resistant
to dl1520 replication, whereas Bischoff et al.
(7) and Heise et al. (13) described
U373 cells to be permissive for dl1520
replication. In addition, inactivation of transcriptionally
active wt p53 in dl1520-resistant U2OS cells did not render
the cells permissive for dl1520 replication. In our studies
dl1520 replication seems, therefore, to be independent of
the p53 status in tumor cells. Finally, we show that the deleted virus
is able to replicate in and kill primary human cells in a multiplicity
of infection (MOI)-dependent manner.
| |
MATERIALS AND METHODS |
Cell culture.
Dulbecco modified Eagle medium (DMEM), RPMI,
cell culture supplements, and serum were obtained from Life
Technologies (Gibco BRL, Eggenstein, Germany), and keratinocyte growth
medium was obtained from Promocell (Heidelberg, Germany). HeLa, 911, H1299, U373, C33a, U87, A549, and U2OS cells were maintained as
monolayers in DMEM; RKO cells were maintained in RPMI supplemented with
10% fetal calf serum (FCS) according to standard procedures. Normal single-donor primary human mammary epithelial cells (MEC; donor age, 24 years) were prepared and maintained as described previously (3,
34). Foreskin keratinocytes (donor 105; age, 5 years) and
foreskin fibroblasts (donors 105 and 106; age, 6 years) were prepared
essentially as described earlier (23). For cultivation of
isolated foreskin keratinocytes, the plates were coated with a mixture
of fibronectin (0.001% [wt/vol]), collagen (0.003% [wt/vol]), and
bovine serum albumin (0.01% [wt/vol]). The foreskin fibroblasts were
maintained in DMEM supplemented with 10% FCS, and the foreskin keratinocytes were maintained in keratinocyte growth medium
(20).
Viruses.
Adenovirus wt (adenovirus type 2 [Ad2]) and
dl1520 were propagated in 911 cells (9) and
purified as described earlier (26). The titer of the frozen
viral stocks of Ad2 (4.9 × 1010 PFU/ml) and
dl1520 (3.2 × 1010 PFU/ml) was determined
by plaque assay with 911 cells (9). The point mutation and
deletion (5) in the dl1520 stocks (preventing the
expression of the E1B 55K gene product) was confirmed by sequencing the
respective genomic region (data not shown). In addition, PCR procedures
were performed to exclude the possibility of wt adenovirus contamination in dl1520 stocks (data not shown). One day
before infection, 3 × 105 cells were plated in
duplicate onto 6-well dishes. Cells were incubated in 0.3 ml of
appropriate serum-free medium containing the adenovirus wt virus (Ad2)
or dl1520 at an MOI of 1 or 100 PFU per cell. After 1 h
of incubation at 37°C with gentle swirling every 10 min, 3 ml of the
respective growth medium was added to each dish. After 5 h the
medium was replaced with 3 ml of fresh growth medium. For infection at
an MOI of 100, the cells were washed twice with phosphate-buffered
saline before fresh medium was added. After 72 h the cells were
scraped into the culture medium and lysed by three cycles of freezing
and thawing, and the supernatant was tested for virus production by
plaque assay in 911 cells (9). Duplicates were titrated
independently. As controls, cells were harvested immediately after
fresh medium was added (5 h postinfection), and the remaining input
virus was determined. For infection at an MOI of 1 PFU per cell, the
titer was <5 × 103 PFU/ml, and for infection at an
MOI of 100 PFU per cell, the titer was <5 × 104
PFU/ml. All viral titers, determined at 72 h postinfection, were at least 2 orders of magnitude higher, indicating that we determined the amount of newly produced virus at this time period. For cytopathic effect (CPE) assays the medium was not changed after 5 h.
Plaque assay.
At 72 h postinfection, the cells were
scraped into the culture medium and lysed by three cycles of freezing
and thawing, and the supernatant was tested for virus production by
plaque assay in 911 cells (9). In brief, the supernatant was
serially diluted in DMEM, and 0.3-ml portions of the dilutions were
added to a 90% confluent 911 cell monolayer on 6-well dishes in
duplicates. After 1 h of incubation at 37°C with gentle swirling
every 10 min, 3 ml of 1% SeaPlaque agarose (FMC, Rockland, Maine) in
DMEM supplemented with 3% FCS was added to each dish. The cells were fed with an additional overlay 4 days later. The plaques were visualized by staining with neutral red in an agarose overlay at 7 days
after infection.
CPE assays.
At the indicated time points postinfection the
cells were stained with crystal violet or photomicrographs were taken.
For staining with crystal violet medium was removed, and the cells were
fixed for 3 min in 3.7% formaldehyde at room temperature. The
formaldehyde was discarded, and the cells were incubated for 3 min in
1% crystal violet. After the staining, the crystal violet solution was
removed, and the cells were rinsed two times in 3 ml of water and then
air dried.
Luciferase assay.
One day before transfection, 3 × 105 cells were plated in triplicate into 6-well dishes. The
cells were transfected with 2 µg of luciferase reporter vector p53CON
(p53 responsive) or pGUP.PA.8 (negative control) (10) from
two independent plasmid preparations by Lipofectamine (Life
Technologies, Eggenstein, Germany) according to the manufacturer's
instructions. Lysates were prepared 48 h after transfection, and
luciferase assays were performed as reported previously
(26).
U2OS cell cloning.
Logarithmically growing U2OS cells were
transfected by Lipofectamine with pRc/CMV/p53-135 (substitution of
cysteine at p53 codon 135 by tyrosine). G418 (Life Technologies) was
added to a final concentration of 180 µg/ml at 48 h
posttransfection. U2OS cells were cloned and tested by Western blot
analysis with antibody p53(Ab6) (Dianova, Hamburg, Germany) for
increased p53 protein expression according to standard procedures.
| |
RESULTS |
Replication of dl1520 in human tumor cell lines with
different p53 status.
Since oncosuppressive and
antiproliferative effects also have been described for
adeno-associated virus infections (4, 16), we
initially became interested in analyzing whether
coamplification with adeno-associated virus would increase the
antitumor effect of dl1520 (i.e., ONYX-015) in vivo. In
initial experiments we attempted to confirm the results revealing
selective growth of dl1520 in p53-negative cells
(7). For this a panel of p53-positive and -negative cell
lines derived from different tissues was infected with wt
adenovirus or with dl1520, respectively, at an MOI of 1 (defined as plaque forming units per cell). At 72 h postinfection, the viral titers were determined by a plaque assay (9) (Fig. 1A). In agreement with the results
reported previously (7), our data confirmed
dl1520 replication in the p53-negative cell line C33a
(cervical carcinoma, p53 codon 273 mutation) and inhibition of
replication in the p53-positive cell line U2OS (osteosarcoma), in which
dl1520 virus yields were reduced by more than 2 orders of
magnitude (Fig. 1A). However, apart from the results for the positive
control cell line 911, in which the E1B 55K is complemented by an
integrated copy of the adenoviral E1 region (9), replication of dl1520 in all other cell lines was independent of the p53
status. In our studies, dl1520 titer was more than 100-fold
lower in p53-negative U373 glioblastoma cells (p53 codon 273 mutation),
while in the p53-positive A549 lung carcinoma, RKO colon carcinoma, and
U87 glioblastoma cells, we obtained only a 1.9- to 3.7-fold inhibition compared to wt adenovirus infection. The overall low titers obtained in
RKO cells can be explained by the low infectability of these cells, as determined by infection with a recombinant adenovirus expressing the 
-galactosidase reporter gene (data not shown). Furthermore, in H1299 (lung carcinoma, p53 null) and HeLa cells (cervical carcinoma, p53 inactivated by E6 of human
papillomavirus-18 (HPV-18 [29-32]) we found
a 27- to 29-fold inhibition of dl1520 compared to wt
adenovirus.
View larger version (43K):
[in this window]
[in a new window]
|
FIG. 1.
(A) Replication efficiency of dl1520 (shaded
bar) and wt adenovirus (Ad2) (open bar) in various cell lines, each
with a different p53 status as indicated in the figure (p53 negative;
p53 null [H1299] or mutant [U373 and C33a contain p53 codon 273 mutation]). U2OS-9 and U2OS-12 cells are clones of parental U2OS cells
expressing mutant p53 (p53 codon 135 mutation). All cells were infected
at an MOI of 1 PFU per cell with either Ad2 or dl1520, and
virus production was measured at 72 h postinfection by plaque
assay. Dots represent the average values of duplicate determinations of
a single infection. The bars represent the mean of 2 to 4 independent
infections. At the top of the column, the fold inhibition of
dl1520 replication compared to Ad2 is given as the ratio of
Ad2 titer (PFU/milliliter) to dl1520 titer (PFU/milliliter).
(B) Determination of transcriptionally active endogenous p53 in various
cell lines by transactivation of a p53-responsive reporter plasmid.
Relative luciferase activities of p53-responsive reporter plasmid
p53CON (solid bar) are expressed as the fold activation above the basic
vector pGUP.PA.8 (shaded bar) after transfection of the indicated
cells. The results represent the average values of at least three
independent transfections, each performed in triplicate. (C) Detection
of mutant p53 (p53mt; codon 135 mutation) in the U2OS-derived cell
clones U2OS-9 and U2OS-12 by Western blotting.
|
|
Measurement of transcriptionally active p53 in human tumor
cell lines.
In transient-transfection assays with
p53-responsive reporter plasmids (10), we confirmed
both the absence of transcriptionally active p53 in the p53-negative
cell lines H1299 and U373 and the presence of transcriptionally active
p53 in the p53-positive cell lines RKO, U87, A549, and U2OS (Fig. 1B).
As previously mentioned, dl1520 replication was inhibited in
only one p53-positive cell line (U2OS); however, a comparable
inhibition (>100 fold) also occurred in the p53-negative cell line
U373. We therefore observed no correlation between the presence of
transcriptionally active p53 and the ability of dl1520 to
replicate in cells.
Expression of transdominant-negative mutant p53 in U2OS cell
clones.
To further confirm that dl1520 replication is
not dependent on the p53 status, we performed experiments to
examine the permissiveness for virus replication in cells in
which p53 was inactivated. To this end, U2OS cell clones
expressing a dominant negative p53 allele (p53 codon 135 mutation) were established. Two of the clones (U2OS-9 and
U2OS-12) expressing the highest level of mutant p53, as determined
by Western blot analysis (Fig. 1C), were tested in
transient transfections for p53 transactivation activity and in
infections for their ability to replicate the deleted adenovirus. While
the transcriptional activity of p53 in these cells was reduced to 10%
of the parental U2OS cells (Fig. 1B), neither clone showed an increased
permissiveness for dl1520 production (Fig. 1A). This finding
is consistent with our results with the various tumor cell lines (Fig.
1A) and indicates that the p53 status in tumor cells does not correlate
with dl1520 replication.
Replication of dl1520 in primary cells at different
MOIs.
We subsequently tested the ability of dl1520 to
replicate in primary cells. For this, we determined virus replication
titers in adult human mammary epithelial cells (MEC), in foreskin
keratinocytes (FK105), and in foreskin fibroblasts (FF105 and FF106),
at 3 days postinfection at MOIs of 1 and 100 (Fig.
2). While at an MOI of 1 replication of dl1520 was reduced 20 to 48 fold, at an MOI
of 100 replication approached wt adenovirus levels (1.5- to
4.3-fold reduction) (Fig. 2). The primary cells were then tested for
the sensitivity to dl1520 and wt adenovirus
infection at MOIs of 0.01 to 100 in CPE assays. As controls, the
p53-negative cell line C33a (cervical carcinoma, p53 codon 273 mutation) and the p53-positive cell line U2OS (osteosarcoma) were
infected in parallel. The CPE was monitored by staining the remaining
cells on the plate with crystal violet. While U2OS cells were resistant
against dl1520 infection at MOIs of 1 and less, wt
adenovirus killed U2OS cells at MOIs of 0.1 to 0.01 (Fig.
3). C33a cells were killed with
comparable efficiency by dl1520 and wt adenovirus at MOIs of
0.1 to 0.01 (Fig. 3). In all of the primary cell types tested, both
viruses exhibited increasing CPEs with increasing MOIs. In
MEC dl1520 was about 10-fold less cytopathic than wt
adenovirus (see especially the MOI of 0.1; Fig. 3). In keratinocytes
and fibroblasts, hardly any difference in terms of CPE
between dl1520 and wt adenovirus-infected cells was
apparent (Fig. 3). It should be noted that fibroblasts were found to be
more resistant to adenovirus-induced CPE than were MEC and
keratinocytes. Only at an MOI of 10 was destruction of the fibroblast
monolayer observed at 9 days postinfection (Fig. 3). The resistance of
fibroblasts to adenovirus-induced CPE correlated with the lower
infectability of fibroblasts, as determined by infection with a
recombinant adenovirus expressing the -galactosidase reporter gene
(data not shown). To monitor the CPE in more detail, we evaluated the
dl1520 and wt adenovirus-infected cells by taking photomicrographs of the cell cultures in a time course of infection with initial MOIs of 10 for fibroblasts and 1 for keratinocytes and MEC
(Fig. 4A
to C). While mock-infected cells showed no CPE, adenovirus wt- and
dl1520-infected primary cells showed a weak CPE at 3 days postinfection and a comparably strong CPE at 8 to 9 days
postinfection (Fig. 4A to C). It should be noted that fibroblasts showed a morphological difference in the CPE upon wt adenovirus and
dl1520 infection (Fig. 4A). While wt adenovirus-infected
fibroblasts are rounded by 9 days after infection,
dl1520 infected cells tend to become more fusiform.
View larger version (34K):
[in this window]
[in a new window]
|
FIG. 2.
Replication efficiency of dl1520 (shaded bar)
and wt adenovirus (Ad2) (open bar) in primary foreskin fibroblasts
(FF105 and FF106), foreskin keratinocytes (FK105), and MEC. Cells were
infected at an MOI of 1 PFU per cell and at an MOI of 100 PFU per cell
(as indicated) with either Ad2 or dl1520. Virus production
was measured 72 h after infection by plaque assay. Dots represent
the average values of duplicate determinations of a single infection.
The bars represent the mean of two independent infections. At the top
of the column, the fold inhibition of dl1520 replication
compared to Ad2 is given as the ratio of Ad2 titer (PFU/milliliter) to
dl1520 titer (PFU/milliliter).
|
|
View larger version (61K):
[in this window]
[in a new window]
|
FIG. 3.
CPE in C33a, U2OS, foreskin fibroblasts (FF105),
foreskin keratinocytes (FK106), and MEC after infection with wt
adenovirus (Ad2) or dl1520. Cells were infected with
increasing MOIs (as indicated) and monitored for CPE by staining of the
remaining cells on the plate with crystal violet (U2OS and C33a, 6 days
after infection; FF105, FK106, and MEC, 9 days after infection).
|
|
MOI dependency of dl1520 replication in tumor
cells.
Since we observed an MOI-dependent replication of
dl1520 in the primary cells, we infected the cell lines
HeLa, H1299, U373, and U2OS, in which we had previously observed
reduced titers at low MOIs, at an MOI of 100. Indeed, under these
conditions, in H1299 (p53 null) and HeLa cells (p53 inactivated by E6
of HPV-18), dl1520 replicated to nearly the same levels as
did wt adenovirus (1.9- to 4.6-fold reduction). In the
p53-positive U2OS cells and the p53-negative U373 cells (p53
codon 273 mutation), however, dl1520 titers were still more
than 100-fold reduced (Fig. 5). These data indicate that the p53 status of a cell alone is also not
responsible for the MOI-dependent replication of dl1520.
View larger version (41K):
[in this window]
[in a new window]
|
FIG. 5.
Replication efficiency of dl1520
(shaded bar) and wt adenovirus (Ad2) (open bar) in HeLa, H1299,
U373, and U2OS cells after infection at an MOI of 100 PFU per cell. The
p53 status of the cell is indicated. Virus production was measured by
plaque assay at 72 h after infection. Dots represent the average
of duplicate determinations. The bars represent the mean of two
independent infections. At the top of the column, the fold inhibition
of dl1520 replication compared to that for Ad2 is given as
the ratio of Ad2 titer (PFU/milliliter) to dl1520 titer
(PFU/milliliter).
|
|
| |
DISCUSSION |
The report from Bischoff et al. (7) indicated a
correlation between the p53 status and the susceptibility to
dl1520 infection. In a CPE assay, it was shown that
dl1520 killed tumor cells lacking normal p53 function but
not cells (primary cells and tumor cells) with normal p53 function
(7). Recently, Heise et al. (13) and Goodrum and
Ornelles (11) reported exceptions to this rule, showing that
some p53-positive tumor cells are susceptible to dl1520
infection. The strongest argument for a p53 dependency of
dl1520 replication came from the results of Bischoff et al. (7), who reported that p53-positive RKO cells (colon
carcinoma) are resistant to dl1520-induced CPE, while
RKO.p53.13 cells, in which wt p53 function has been ablated by
expression of a dominant-negative p53 allele, were 100-fold more
sensitive to a dl1520-induced CPE. In our studies we found
that dl1520 produced as much progeny virus as did wt
adenovirus in RKO cells and that in p53-positive U2OS cells the
inhibition of wt p53 activity by the overexpression of mutant p53 did
not render the cells permissive for dl1520 replication. In
addition, we observed no correlation between the p53 status in U87,
A549, H1299, and U373 cells and the ability of dl1520 to
replicate. While it was reported that U373 cells (p53 codon 273 mutation) were sensitive and U87 cells (p53 wild-type) were resistant
to dl1520 infection in CPE assays (7, 13), our experiments indicated that dl1520 produced nearly as much
progeny virus as did wt adenovirus in p53-positive U87 cells. In the
p53-negative U373 cells, however, the dl1520 titer was
reduced more than 100 fold. The reason for the conflicting results
obtained in the CPE assays compared to the determination of viral
titers remains to be determined. It should be noted, however, that
results obtained in these assays may not be directly comparable
since viral capsid proteins, even in the absence of viral DNA
replication, may induce cytopathic changes (21, 34).
Recently, Ridgway et al. (24) reported that wt adenovirus
does not cause CPE in p53 mutant tumor cells, while we could clearly
show that wt adenovirus produced high titers of progeny virus in the
p53 mutant tumor cells C33a and U373. For these reasons, titrations of
newly produced virus appears to be a better indication for
permissiveness of specific cell types than the morphological evaluation
of infected cells in CPE assays.
It was recently reported that, upon infection of MEC, dl1520
produced 100-fold less infectious virus compared to wt adenovirus (13). In addition, in CPE assays, MEC were found to be
resistant to dl1520-induced CPE at MOIs of 0.01 to 1. In our
experiments, dl1520 replication was 38-fold reduced in MEC
at an MOI of 1, which is consistent with the data reported. However, we
also observed clear signs of CPE by dl1520 infection at MOIs
of 0.1 to 1. This difference may be explained by the use of different
mammary epithelial isolates. Similarly, in human foreskin
keratinocytes and foreskin fibroblasts, while dl1520
replication was clearly inhibited in viral burst experiments, the
differences between dl1520 and wt adenovirus-induced CPE
were even less remarkable. Thus, these primary cells are
less permissive for dl1520 replication, yet they
are still sensitive to the dl1520-induced killing effect.
In the present study we found an MOI-dependent dl1520
replication in the tumor cell lines H1299 (p53 null) and HeLa
(p53 inactivated by E6 of HPV-18), while in the tumor cell
lines U2OS (wt p53) and U373 (p53 codon 273 mutation) the replication
of dl1520, even at high MOIs, was reduced more than 100 fold
compared to wt adenovirus. Similarly, as previously reported, an
increase in virus replication of different E1B-deleted adenoviruses
correlated with an increase of the MOI in HeLa cells (1, 6,
33). Our data extend this observation, indicating that E1B is
also dispensable for virulent virus replication at high MOIs of
infection in adult human primary cells. In addition, we have shown that
the MOI-dependent phenotype of dl1520 replication does not
correlate with the p53 status of a cell. It is presently unknown
whether the ability of the deleted virus to replicate in normal
cells in vitro is also reflected in the in vivo situation,
i.e., the patient with cancer. In a recent publication, an
S-phase dependence for dl1520 replication was shown in HeLa
cells (11). Since we tested tumor and primary cells under
proliferating conditions in vitro, it is possible that
dl1520 replication may occur preferentially in
fast-proliferating tumor cells under in vivo conditions. The direct
injection of dl1520 into the tumor mass, leading to a high
local virus dose and high MOIs only in tumor cells, may also help to
prevent undesired virus replication in normal cells. For the same
reasons, systemic administration of the virus in combination with
chemotherapy, as recently suggested by Heise et al. (13),
does not appeal as a rational concept for the use of dl1520
in cancer therapy.
Bischoff et al. (7) could show that a U2OS cell line
stably expressing the E1B 55-kDa protein complements for
dl1520 replication, while we found that inactivation
of transcriptionally active p53 in U2OS by overexpression of a mutant
p53 does not complement for dl1520 replication. However, in
both of the mutant p53-containing U2OS cell lines, the residual amount
of transcriptional active p53 is comparable (ca. 10% of the parental
level). It seems likely, therefore, that other functions of E1B, apart
from inactivation of p53, are necessary for efficient virus replication
in U2OS cells. It has been shown that during the late stage of
lytic adenovirus infection, the E1B protein in complex with E4
34-kDa preferentially facilitates the transport of viral mRNA, while
the export of most cellular RNAs is inhibited (2, 8, 12, 17, 19,
22, 27). As a consequence, adenoviral mutants that failed to
express E1B were defective for late viral protein expression and the
titers are low. It is possible that as-yet-unknown mechanisms in some tumor cells may complement for the E1B RNA transport functions and, as
a result, in these cells the titers of E1B-deleted viruses are
comparable to those of wt adenovirus. Furthermore, Bischoff et al.
(7) reported that a stable U2OS cell line expressing an
E1B deletion mutant that is unable to bind to p53 does not complement
for dl1520 replication. This indicates that while the p53
status does not appear to be relevant, the epitope of E1B which is
involved in binding to p53 is important. This may suggest that the
interaction of E1B with p53-related proteins, such as the newly
discovered p73 protein, may be crucial for adenovirus replication
(15).
In this study, we could clearly demonstrate that the p53
status of a tumor cell alone does not determine the ability of
dl1520 to replicate. Therefore, the p53 status does not
appear to be a suitable marker for the prognosis of dl1520
replication and tumor destruction. In addition, we could show that
dl1520 was able to kill and replicate in human primary
cells in a manner dependent on the MOI. Moreover, while it appears that
some tumor cells (C33a, A549, and U87) are more permissive for
dl1520 replication than are primary cells, others
(U2OS and U373) are even more resistant to the deleted virus. The
molecular basis for the growth differences of dl1520 within
these different cell types remains to be determined.
| |
ACKNOWLEDGMENTS |
We thank A. Berk (University of California, Los Angeles, Calif.)
for providing dl1520 virus, J. M. Shay (University of
Texas, Dallas, Tex.) for plasmids p53CON and P53GUP.PA.8, A. van der Eb
for 911 cells, and R. Schmidt (Angewandte Tumorvirologie, Deutsches Krebsforschungszentrum, Heidelberg, Germany) for help with culturing the primary cells.
This work was supported by the Jung-Stiftung-Hamburg.
| |
FOOTNOTES |
*
Corresponding author. Mailing address: Deutsches
Krebsforschungszentrum, Im Neuenheimer Feld 240, 69120 Heidelberg,
Germany. Phone: 49-6221-422850. Fax: 49-6221-422840. E-mail:
zurhausen{at}dkfz-heidelberg@de.
| |
REFERENCES |
| 1.
|
Babiss, L. E., and H. S. Ginsberg.
1984.
Adenovirus type 5 early region 1b gene product is required for efficient shutoff of host protein synthesis.
J. Virol.
50:202-212[Abstract/Free Full Text].
|
| 2.
|
Babiss, L. E.,
H. S. Ginsberg, and J. E. Darnell, Jr.
1985.
Adenovirus E1B proteins are required for accumulation of late viral mRNA and for effects on cellular mRNA translation and transport.
Mol. Cell. Biol.
5:2552-2558[Abstract/Free Full Text].
|
| 3.
|
Band, V., and R. Sager.
1989.
Distinctive traits of normal and tumor-derived human mammary epithelial cells expressed in a medium that supports long-term growth of both cell types.
Proc. Natl. Acad. Sci. USA
86:1249-1253[Abstract/Free Full Text].
|
| 4.
|
Bantel Schaal, U.
1990.
Adeno-associated parvoviruses inhibit growth of cells derived from malignant human tumors.
Int. J. Cancer
45:190-194[Medline].
|
| 5.
|
Barker, D. D., and A. J. Berk.
1987.
Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection.
Virology
156:107-121[Medline]. (Erratum, 158:263.)
|
| 6.
|
Bernards, R.,
M. G. de Leeuw,
A. Houweling, and A. J. van der Eb.
1986.
Role of the adenovirus early region 1B tumor antigens in transformation and lytic infection.
Virology
150:126-139[Medline].
|
| 7.
|
Bischoff, J. R.,
D. H. Kirn,
A. Williams,
C. Heise,
S. Horn,
M. Muna,
L. Ng,
J. A. Nye,
A. Sampson Johannes,
A. Fattaey, et al.
1996.
An adenovirus mutant that replicates selectively in p53-deficient human tumor cells [see comments].
Science
274:373-376[Abstract/Free Full Text].
|
| 8.
|
Dobbelstein, M.,
J. Roth,
W. T. Kimberly,
A. J. Levine, and T. Shenk.
1997.
Nuclear export of the E1B 55-kDa and E4 34-kDa adenoviral oncoproteins mediated by a rev-like signal sequence.
EMBO J.
16:4276-4284[Medline].
|
| 9.
|
Fallaux, F. J.,
O. Kranenburg,
S. J. Cramer,
A. Houweling,
H. Van Ormondt,
R. C. Hoeben, and A. J. van der Eb.
1996.
Characterization of 911: a new helper cell line for the titration and propagation of early region 1-deleted adenoviral vectors.
Hum. Gene Ther.
7:215-222[Medline].
|
| 10.
|
Funk, W. D.,
D. T. Pak,
R. H. Karas,
W. E. Wright, and J. W. Shay.
1992.
A transcriptionally active DNA-binding site for human p53 protein complexes.
Mol. Cell. Biol.
12:2866-2871[Abstract/Free Full Text].
|
| 11.
|
Goodrum, F. D., and D. A. Ornelles.
1997.
The early region 1B 55-kDa oncoprotein of adenovirus relieves growth restrictions imposed on viral replication by the cell cycle.
J. Virol.
71:548-561[Abstract].
|
| 12.
|
Halbert, D. N.,
J. R. Cutt, and T. Shenk.
1985.
Adenovirus early region 4 encodes functions required for efficient DNA replication, late gene expression, and host cell shutoff.
J. Virol.
56:250-257[Abstract/Free Full Text].
|
| 13.
|
Heise, C.,
A. Sampson Johannes,
A. Williams,
F. McCormick,
D. D. Von Hoff, and D. H. Kirn.
1997.
ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents.
Nat. Med.
3:639-645[Medline].
|
| 14.
|
Hollstein, M.,
D. Sidransky,
B. Vogelstein, and C. C. Harris.
1991.
p53 mutations in human cancers.
Science
253:49-53[Abstract/Free Full Text].
|
| 15.
|
Kaghad, M.,
H. Bonnet,
A. Yang,
L. Creancier,
J. C. Biscan,
A. Valent,
A. Minty,
P. Chalon,
J. M. Lelias,
X. Dumont,
P. Ferrara,
F. McKeon, and D. Caput.
1997.
Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers.
Cell
90:809-819[Medline].
|
| 16.
|
Katz, E., and B. J. Carter.
1986.
Effect of adeno-associated virus on transformation of NIH 3T3 cells by ras gene and on tumorigenicity of an NIH 3T3 transformed cell line.
Cancer Res.
46:3023-3026[Abstract/Free Full Text].
|
| 17.
|
Leppard, K. N., and T. Shenk.
1989.
The adenovirus E1B 55-kd protein influences mRNA transport via an intranuclear effect on RNA metabolism.
EMBO J.
8:2329-2336[Medline].
|
| 18.
|
Levine, A. J.,
J. Momand, and C. A. Finlay.
1991.
The p53 tumour suppressor gene.
Nature
351:453-456[Medline].
|
| 19.
|
Logan, J. S., and T. Shenk.
1982.
Transcriptional and translational control of adenovirus gene expression.
Microbiol. Rev.
46:377-383[Free Full Text].
|
| 20.
|
Peehl, D. M., and R. G. Ham.
1980.
Growth and differentiation of human keratinocytes without a feeder layer or conditioned medium.
In Vitro (Rockville)
16:516-525[Medline].
|
| 21.
|
Pereira, H. G.
1958.
A protein factor responsible for early cytopathic effect of adenoviruses.
Virology
6:601-611[Medline].
|
| 22.
|
Pilder, S.,
M. Moore,
J. Logan, and T. Shenk.
1986.
The adenovirus E1B-55K transforming polypeptide modulates transport or cytoplasmic stabilization of viral and host cell mRNAs.
Mol. Cell Biol.
6:470-476[Abstract/Free Full Text].
|
| 23.
|
Rheinwald, J. G., and H. Green.
1975.
Serial cultivation of strains of human epidermal keratinocytes: the formation of keratinizing colonies from single cells.
Cell
6:331-343[Medline].
|
| 24.
|
Ridgway, P. J.,
A. R. Hall,
C. J. Myers, and A. W. Braithwaite.
1997.
p53/E1b 58-kDa complex regulates adenovirus replication.
Virology
237:404-413[Medline].
|
| 25.
|
Roth, J. A., and R. J. Cristiano.
1997.
Gene therapy for cancer: what have we done and where are we going?
J. Natl. Cancer Inst.
89:21-39[Abstract/Free Full Text].
|
| 26.
|
Rothmann, T.,
H. A. Katus,
R. Hartong,
M. Perricaudet, and W. M. Franz.
1996.
Heart muscle-specific gene expression using replication defective recombinant adenovirus.
Gene Ther.
3:919-926[Medline].
|
| 27.
|
Sarnow, P.,
P. Hearing,
C. W. Anderson,
D. N. Halbert,
T. Shenk, and A. J. Levine.
1984.
Adenovirus early region 1B 58,000-dalton tumor antigen is physically associated with an early region 4 25,000-dalton protein in productively infected cells.
J. Virol.
49:692-700[Abstract/Free Full Text].
|
| 28.
|
Sarnow, P.,
Y. S. Ho,
J. Williams, and A. J. Levine.
1982.
Adenovirus E1b-58kd tumor antigen and SV40 large tumor antigen are physically associated with the same 54 kd cellular protein in transformed cells.
Cell
28:387-394[Medline].
|
| 29.
|
Scheffner, M.,
J. M. Huibregtse,
R. D. Vierstra, and P. M. Howley.
1993.
The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53.
Cell
75:495-505[Medline].
|
| 30.
|
Scheffner, M.,
K. Munger,
J. C. Byrne, and P. M. Howley.
1991.
The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines.
Proc. Natl. Acad. Sci. USA
88:5523-5527[Abstract/Free Full Text].
|
| 31.
|
Scheffner, M.,
B. A. Werness,
J. M. Huibregtse,
A. J. Levine, and P. M. Howley.
1990.
The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53.
Cell
63:1129-1136[Medline].
|
| 32.
|
Schwarz, E.,
U. K. Freese,
L. Gissmann,
W. Mayer,
B. Roggenbuck,
A. Stremlau, and H. zur Hausen.
1985.
Structure and transcription of human papillomavirus sequences in cervical carcinoma cells.
Nature
314:111-114[Medline].
|
| 33.
|
Shenk, T.,
N. Jones,
W. Colby, and D. Fowlkes.
1980.
Functional analysis of adenovirus-5 host-range deletion mutants defective for transformation of rat embryo cells.
Cold Spring Harb. Symp. Quant. Biol.
44(pt.1):367-375.
|
| 34.
|
Stampfer, M. R.
1985.
Isolation and growth of human mammary epithelial cells.
J. Tissue Cult. Methods
9:107.
|
| 35.
|
Valentine, R. C., and H. G. Pereira.
1965.
Antigens and structure of the adenovirus.
J. Mol. Biol.
13:13-20[Medline].
|
| 36.
|
Verma, I. M., and N. Somia.
1997.
Gene therapy promises, problems and prospects [news].
Nature
389:239-242[Medline].
|
| 37.
|
Yew, P. R., and A. J. Berk.
1992.
Inhibition of p53 transactivation required for transformation by adenovirus early 1B protein.
Nature
357:82-85[Medline].
|
| 38.
|
Yew, P. R.,
X. Liu, and A. J. Berk.
1994.
Adenovirus E1B oncoprotein tethers a transcriptional repression domain to p53.
Genes Dev.
8:190-202[Abstract/Free Full Text].
|
Journal of Virology, December 1998, p. 9470-9478, Vol. 72, No. 12
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Gurlevik, E., Woller, N., Schache, P., Malek, N. P., Wirth, T. C., Zender, L., Manns, M. P., Kubicka, S., Kuhnel, F.
(2009). p53-dependent antiviral RNA-interference facilitates tumor-selective viral replication. Nucleic Acids Res
37: e84-e84
[Abstract]
[Full Text]
-
Blackford, A. N., Grand, R. J. A.
(2009). Adenovirus E1B 55-Kilodalton Protein: Multiple Roles in Viral Infection and Cell Transformation. J. Virol.
83: 4000-4012
[Full Text]
-
Zheng, X., Rao, X.-M., Gomez-Gutierrez, J. G., Hao, H., McMasters, K. M., Zhou, H. S.
(2008). Adenovirus E1B55K Region Is Required To Enhance Cyclin E Expression for Efficient Viral DNA Replication. J. Virol.
82: 3415-3427
[Abstract]
[Full Text]
-
Wakayama, M., Abei, M., Kawashima, R., Seo, E., Fukuda, K., Ugai, H., Murata, T., Tanaka, N., Hyodo, I., Hamada, H., Yokoyama, K. K.
(2007). E1A, E1B Double-Restricted Adenovirus with RGD-Fiber Modification Exhibits Enhanced Oncolysis for CAR-Deficient Biliary Cancers. Clin. Cancer Res.
13: 3043-3050
[Abstract]
[Full Text]
-
Woo, J. L., Berk, A. J.
(2007). Adenovirus Ubiquitin-Protein Ligase Stimulates Viral Late mRNA Nuclear Export. J. Virol.
81: 575-587
[Abstract]
[Full Text]
-
Hiraoka, K., Kimura, T., Logg, C. R., Kasahara, N.
(2006). Tumor-Selective Gene Expression in a Hepatic Metastasis Model after Locoregional Delivery of a Replication-Competent Retrovirus Vector. Clin. Cancer Res.
12: 7108-7116
[Abstract]
[Full Text]
-
Gonzalez, R., Huang, W., Finnen, R., Bragg, C., Flint, S. J.
(2006). Adenovirus E1B 55-Kilodalton Protein Is Required for both Regulation of mRNA Export and Efficient Entry into the Late Phase of Infection in Normal Human Fibroblasts. J. Virol.
80: 964-974
[Abstract]
[Full Text]
-
Kamizono, J., Nagano, S., Murofushi, Y., Komiya, S., Fujiwara, H., Matsuishi, T., Kosai, K.-i.
(2005). Survivin-Responsive Conditionally Replicating Adenovirus Exhibits Cancer-Specific and Efficient Viral Replication. Cancer Res.
65: 5284-5291
[Abstract]
[Full Text]
-
Fischer, U., Schulze-Osthoff, K.
(2005). New Approaches and Therapeutics Targeting Apoptosis in Disease. Pharmacol. Rev.
57: 187-215
[Abstract]
[Full Text]
-
Curiel, D. T.
(2005). Next Generation CRAds for Virotherapy of Cancer. aacredbook
2005: 141-144
[Full Text]
-
Abou El Hassan, M. A. I., van der Meulen-Muileman, I., Abbas, S., Kruyt, F. A. E.
(2004). Conditionally Replicating Adenoviruses Kill Tumor Cells via a Basic Apoptotic Machinery-Independent Mechanism That Resembles Necrosis-Like Programmed Cell Death. J. Virol.
78: 12243-12251
[Abstract]
[Full Text]
-
Starita, L. M., Machida, Y., Sankaran, S., Elias, J. E., Griffin, K., Schlegel, B. P., Gygi, S. P., Parvin, J. D.
(2004). BRCA1-Dependent Ubiquitination of {gamma}-Tubulin Regulates Centrosome Number. Mol. Cell. Biol.
24: 8457-8466
[Abstract]
[Full Text]
-
Chu, R. L., Post, D. E., Khuri, F. R., Van Meir, E. G.
(2004). Use of Replicating Oncolytic Adenoviruses in Combination Therapy for Cancer. Clin. Cancer Res.
10: 5299-5312
[Abstract]
[Full Text]
-
Maemondo, M., Saijo, Y., Narumi, K., Kikuchi, T., Usui, K., Tazawa, R., Matsumoto, K., Nakamura, T., Sasaki, K., Takahashi, M., Niitsu, Y., Nukiwa, T.
(2004). Gene Therapy with Secretory Leukoprotease Inhibitor Promoter-Controlled Replication-Competent Adenovirus for Non-Small Cell Lung Cancer. Cancer Res.
64: 4611-4620
[Abstract]
[Full Text]
-
Morley, S., MacDonald, G., Kirn, D., Kaye, S., Brown, R., Soutar, D.
(2004). The dl1520 Virus Is Found Preferentially in Tumor Tissue after Direct Intratumoral Injection in Oral Carcinoma. Clin. Cancer Res.
10: 4357-4362
[Abstract]
[Full Text]
-
Barzon, L., Boscaro, M., Palu, G.
(2004). Endocrine Aspects of Cancer Gene Therapy. Endocr. Rev.
25: 1-44
[Abstract]
[Full Text]
-
Rudin, C. M., Cohen, E. E.W., Papadimitrakopoulou, V. A., Silverman, S. Jr, Recant, W., El-Naggar, A. K., Stenson, K., Lippman, S. M., Hong, W. K., Vokes, E. E.
(2003). An Attenuated Adenovirus, ONYX-015, As Mouthwash Therapy for Premalignant Oral Dysplasia. JCO
21: 4546-4552
[Abstract]
[Full Text]
-
Ganly, I., Singh, B.
(2003). Topical ONYX-015 in the Treatment of Premalignant Oral Dysplasia: Another Role for the Cold Virus?. JCO
21: 4476-4478
[Full Text]
-
Patry, C., Bouchard, L., Labrecque, P., Gendron, D., Lemieux, B., Toutant, J., Lapointe, E., Wellinger, R., Chabot, B.
(2003). Small Interfering RNA-Mediated Reduction in Heterogeneous Nuclear Ribonucleoparticule A1/A2 Proteins Induces Apoptosis in Human Cancer Cells but not in Normal Mortal Cell Lines. Cancer Res.
63: 7679-7688
[Abstract]
[Full Text]
-
Hann, B., Balmain, A.
(2003). Replication of an E1B 55-Kilodalton Protein-Deficient Adenovirus (ONYX-015) Is Restored by Gain-of-Function Rather than Loss-of-Function p53 Mutants. J. Virol.
77: 11588-11595
[Abstract]
[Full Text]
-
Moon, C., Oh, Y., Roth, J. A.
(2003). Current Status of Gene Therapy for Lung Cancer and Head and Neck Cancer. Clin. Cancer Res.
9: 5055-5067
[Abstract]
[Full Text]
-
Portella, G., Pacelli, R., Libertini, S., Cella, L., Vecchio, G., Salvatore, M., Fusco, A.
(2003). ONYX-015 Enhances Radiation-Induced Death of Human Anaplastic Thyroid Carcinoma Cells. J. Clin. Endocrinol. Metab.
88: 5027-5032
[Abstract]
[Full Text]
-
Fukuda, K., Abei, M., Ugai, H., Seo, E., Wakayama, M., Murata, T., Todoroki, T., Tanaka, N., Hamada, H., Yokoyama, K. K.
(2003). E1A, E1B Double-restricted Adenovirus for Oncolytic Gene Therapy of Gallbladder Cancer. Cancer Res.
63: 4434-4440
[Abstract]
[Full Text]
-
Wirth, T., Zender, L., Schulte, B., Mundt, B., Plentz, R., Rudolph, K. L., Manns, M., Kubicka, S., Kuhnel, F.
(2003). A Telomerase-dependent Conditionally Replicating Adenovirus for Selective Treatment of Cancer. Cancer Res.
63: 3181-3188
[Abstract]
[Full Text]
-
Yan, W., Kitzes, G., Dormishian, F., Hawkins, L., Sampson-Johannes, A., Watanabe, J., Holt, J., Lee, V., Dubensky, T., Fattaey, A., Hermiston, T., Balmain, A., Shen, Y.
(2003). Developing Novel Oncolytic Adenoviruses through Bioselection. J. Virol.
77: 2640-2650
[Abstract]
[Full Text]
-
Hecht, J. R., Bedford, R., Abbruzzese, J. L., Lahoti, S., Reid, T. R., Soetikno, R. M., Kirn, D. H., Freeman, S. M.
(2003). A Phase I/II Trial of Intratumoral Endoscopic Ultrasound Injection of ONYX-015 with Intravenous Gemcitabine in Unresectable Pancreatic Carcinoma. Clin. Cancer Res.
9: 555-561
[Abstract]
[Full Text]
-
Makower, D., Rozenblit, A., Kaufman, H., Edelman, M., Lane, M. E., Zwiebel, J., Haynes, H., Wadler, S.
(2003). Phase II Clinical Trial of Intralesional Administration of the Oncolytic Adenovirus ONYX-015 in Patients with Hepatobiliary Tumors with Correlative p53 Studies. Clin. Cancer Res.
9: 693-702
[Abstract]
[Full Text]
-
Wadler, S., Yu, B., Tan, J.-Y., Kaleya, R., Rozenblit, A., Makower, D., Edelman, M., Lane, M., Hyjek, E., Horwitz, M.
(2003). Persistent Replication of the Modified Chimeric Adenovirus ONYX-015 in both Tumor and Stromal Cells from a Patient with Gall Bladder Carcinoma Implants. Clin. Cancer Res.
9: 33-43
[Abstract]
[Full Text]
-
Hsieh, J.-L., Wu, C.-L., Lee, C.-H., Shiau, A.-L.
(2003). Hepatitis B Virus X Protein Sensitizes Hepatocellular Carcinoma Cells to Cytolysis Induced by E1B-deleted Adenovirus through the Disruption of p53 Function. Clin. Cancer Res.
9: 338-345
[Abstract]
[Full Text]
-
Palmer, D. H, Chen, M.-J., Kerr, D. J
(2002). Gene therapy for colorectal cancer. Br Med Bull
64: 201-225
[Abstract]
[Full Text]
-
Edwards, S. J., Dix, B. R., Myers, C. J., Dobson-Le, D., Huschtscha, L., Hibma, M., Royds, J., Braithwaite, A. W.
(2002). Evidence that Replication of the Antitumor Adenovirus ONYX-015 Is Not Controlled by the p53 and p14ARF Tumor Suppressor Genes. J. Virol.
76: 12483-12490
[Abstract]
[Full Text]
-
Reid, T., Galanis, E., Abbruzzese, J., Sze, D., Wein, L. M., Andrews, J., Randlev, B., Heise, C., Uprichard, M., Hatfield, M., Rome, L., Rubin, J., Kirn, D.
(2002). Hepatic Arterial Infusion of a Replication-selective Oncolytic Adenovirus (dl1520): Phase II Viral, Immunologic, and Clinical Endpoints. Cancer Res.
62: 6070-6079
[Abstract]
[Full Text]
-
Bernt, K., Liang, M., Ye, X., Ni, S., Li, Z.-Y., Ye, S. L., Hu, F., Lieber, A.
(2002). A New Type of Adenovirus Vector That Utilizes Homologous Recombination To Achieve Tumor-Specific Replication. J. Virol.
76: 10994-11002
[Abstract]
[Full Text]
-
Tsukuda, K., Wiewrodt, R., Molnar-Kimber, K., Jovanovic, V. P., Amin, K. M.
(2002). An E2F-responsive Replication-selective Adenovirus Targeted to the Defective Cell Cycle in Cancer Cells: Potent Antitumoral Efficacy but No Toxicity to Normal Cell. Cancer Res.
62: 3438-3447
[Abstract]
[Full Text]
-
Mullen, J. T., Tanabe, K. K.
(2002). Viral Oncolysis. The Oncologist
7: 106-119
[Abstract]
[Full Text]
-
Gonzalez, R. A., Flint, S. J.
(2002). Effects of Mutations in the Adenoviral E1B 55-Kilodalton Protein Coding Sequence on Viral Late mRNA Metabolism. J. Virol.
76: 4507-4519
[Abstract]
[Full Text]
-
Holm, P. S., Bergmann, S., Jurchott, K., Lage, H., Brand, K., Ladhoff, A., Mantwill, K., Curiel, D. T., Dobbelstein, M., Dietel, M., Gansbacher, B., Royer, H.-D.
(2002). YB-1 Relocates to the Nucleus in Adenovirus-infected Cells and Facilitates Viral Replication by Inducing E2 Gene Expression through the E2 Late Promoter. J. Biol. Chem.
277: 10427-10434
[Abstract]
[Full Text]
-
Ring, C. J. A.
(2002). Cytolytic viruses as potential anti-cancer agents. J. Gen. Virol.
83: 491-502
[Abstract]
[Full Text]
-
Geoerger, B., Grill, J., Opolon, P., Morizet, J., Aubert, G., Terrier-Lacombe, M.-J., Bressac de-Paillerets, B., Barrois, M., Feunteun, J., Kirn, D. H., Vassal, G.
(2002). Oncolytic Activity of the E1B-55 kDa-deleted Adenovirus ONYX-015 Is Independent of Cellular p53 Status in Human Malignant Glioma Xenografts. Cancer Res.
62: 764-772
[Abstract]
[Full Text]
-
Vorburger, S. A., Hunt, K. K.
(2002). Adenoviral Gene Therapy. The Oncologist
7: 46-59
[Abstract]
[Full Text]
-
Andreu, T., Ebensperger, C., Westphal, E.-M., Klenner, T., Stewart, A. F., Westhof, A., Muller, P., Knaus, R., von Melchner, H.
(2001). Self-deleting Suicide Vectors (SDSV): Selective Killing of p53-deficient Cancer Cells. Cancer Res.
61: 6925-6930
[Abstract]
[Full Text]
-
Koch, P., Gatfield, J., Lober, C., Hobom, U., Lenz-Stoppler, C., Roth, J., Dobbelstein, M.
(2001). Efficient Replication of Adenovirus Despite the Overexpression of Active and Nondegradable p53. Cancer Res.
61: 5941-5947
[Abstract]
[Full Text]
-
Hodges, B. L., Evans, H. K., Everett, R. S., Ding, E. Y., Serra, D., Amalfitano, A.
(2001). Adenovirus Vectors with the 100K Gene Deleted and Their Potential for Multiple Gene Therapy Applications. J. Virol.
75: 5913-5920
[Abstract]
[Full Text]
-
Dix, B. R., Edwards, S. J., Braithwaite, A. W.
(2001). Does the Antitumor Adenovirus ONYX-015/dl1520 Selectively Target Cells Defective in the p53 Pathway?. J. Virol.
75: 5443-5447
[Full Text]
-
Shen, Y., Kitzes, G., Nye, J. A., Fattaey, A., Hermiston, T.
(2001). Analyses of Single-Amino-Acid Substitution Mutants of Adenovirus Type 5 E1B-55K Protein. J. Virol.
75: 4297-4307
[Abstract]
[Full Text]
-
Doronin, K., Kuppuswamy, M., Toth, K., Tollefson, A. E., Krajcsi, P., Krougliak, V., Wold, W. S. M.
(2001). Tissue-Specific, Tumor-Selective, Replication-Competent Adenovirus Vector for Cancer Gene Therapy. J. Virol.
75: 3314-3324
[Abstract]
[Full Text]
-
Brunori, M., Malerba, M., Kashiwazaki, H., Iggo, R.
(2001). Replicating Adenoviruses That Target Tumors with Constitutive Activation of the wnt Signaling Pathway. J. Virol.
75: 2857-2865
[Abstract]
[Full Text]
-
Routes, J. M., Ryan, S., Clase, A., Miura, T., Kuhl, A., Potter, T. A., Cook, J. L.
(2000). Adenovirus E1A Oncogene Expression in Tumor Cells Enhances Killing by TNF-Related Apoptosis-Inducing Ligand (TRAIL). J. Immunol.
165: 4522-4527
[Abstract]
[Full Text]
-
Curiel, D. T.
(2000). The Development of Conditionally Replicative Adenoviruses for Cancer Therapy. Clin. Cancer Res.
6: 3395-3399
[Abstract]
[Full Text]
-
Doronin, K., Toth, K., Kuppuswamy, M., Ward, P., Tollefson, A. E., Wold, W. S. M.
(2000). Tumor-Specific, Replication-Competent Adenovirus Vectors Overexpressing the Adenovirus Death Protein. J. Virol.
74: 6147-6155
[Abstract]
[Full Text]
-
Pawlik, T. M., Nakamura, H., Yoon, S. S., Mullen, J. T., Chandrasekhar, S., Chiocca, E. A., Tanabe, K. K.
(2000). Oncolysis of Diffuse Hepatocellular Carcinoma by Intravascular Administration of a Replication-competent, Genetically Engineered Herpesvirus. Cancer Res.
60: 2790-2795
[Abstract]
[Full Text]
-
Dix, B. R., O’Carroll, S. J., Myers, C. J., Edwards, S. J., Braithwaite, A. W.
(2000). Efficient Induction of Cell Death by Adenoviruses Requires Binding of E1B55k and p53. Cancer Res.
60: 2666-2672
[Abstract]
[Full Text]
-
Rogulski, K. R., Freytag, S. O., Zhang, K., Gilbert, J. D., Paielli, D. L., Kim, J. H., Heise, C. C., Kirn, D. H.
(2000). In Vivo Antitumor Activity of ONYX-015 Is Influenced by p53 Status and Is Augmented by Radiotherapy. Cancer Res.
60: 1193-1196
[Abstract]
[Full Text]
-
YOON, S. S., NAKAMURA, H., CARROLL, N. M., BODE, B. P., CHIOCCA, E. A., TANABE, K. K.
(2000). An oncolytic herpes simplex virus type 1 selectively destroys diffuse liver metastases from colon carcinoma. FASEB J.
14: 301-311
[Abstract]
[Full Text]
-
You, L., Yang, C.-T., Jablons, D. M.
(2000). ONYX-015 Works Synergistically with Chemotherapy in Lung Cancer Cell Lines and Primary Cultures Freshly Made from Lung Cancer Patients. Cancer Res.
60: 1009-1013
[Abstract]
[Full Text]
-
Weigel, S., Dobbelstein, M.
(2000). The Nuclear Export Signal within the E4orf6 Protein of Adenovirus Type 5 Supports Virus Replication and Cytoplasmic Accumulation of Viral mRNA. J. Virol.
74: 764-772
[Abstract]
[Full Text]
-
Hedner, U., Ginsburg, D., Lusher, J. M., High, K. A.
(2000). Congenital Hemorrhagic Disorders: New Insights into the Pathophysiology and Treatment of Hemophilia. ASH Education Book
2000: 241-265
[Abstract]
[Full Text]
-
Goodrum, F. D., Ornelles, D. A.
(1999). Roles for the E4 orf6, orf3, and E1B 55-Kilodalton Proteins in Cell Cycle-Independent Adenovirus Replication. J. Virol.
73: 7474-7488
[Abstract]
[Full Text]
-
Harada, J. N., Berk, A. J.
(1999). p53-Independent and -Dependent Requirements for E1B-55K in Adenovirus Type 5 Replication. J. Virol.
73: 5333-5344
[Abstract]
[Full Text]
-
Shinoura, N., Yoshida, Y., Tsunoda, R., Ohashi, M., Zhang, W., Asai, A., Kirino, T., Hamada, H.
(1999). Highly Augmented Cytopathic Effect of a Fiber-mutant E1B-defective Adenovirus for Gene Therapy of Gliomas. Cancer Res.
59: 3411-3416
[Abstract]
[Full Text]
-
Advani, S. J., Chung, S.-M., Yan, S. Y., Gillespie, G. Y., Markert, J. M., Whitley, R. J., Roizman, B., Weichselbaum, R. R.
(1999). Replication-competent, Nonneuroinvasive Genetically Engineered Herpes Virus Is Highly Effective in the Treatment of Therapy-resistant Experimental Human Tumors. Cancer Res.
59: 2055-2058
[Abstract]
[Full Text]
-
Yu, D.-C., Sakamoto, G. T., Henderson, D. R.
(1999). Identification of the Transcriptional Regulatory Sequences of Human Kallikrein 2 and Their Use in the Construction of Calydon Virus 764, an Attenuated Replication Competent Adenovirus for Prostate Cancer Therapy. Cancer Res.
59: 1498-1504
[Abstract]
[Full Text]
Top
Abstract
Introduction
